- Home
- KPTI vs IPWR Comparison
KPTI vs IPWR Comparison
Compare KPTI & IPWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- IPWR
- Stock Information
- Founded
- KPTI 2008
- IPWR 2007
- Country
- KPTI United States
- IPWR United States
- Employees
- KPTI N/A
- IPWR N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- IPWR Industrial Machinery/Components
- Sector
- KPTI Health Care
- IPWR Industrials
- Exchange
- KPTI Nasdaq
- IPWR Nasdaq
- Market Cap
- KPTI 51.7M
- IPWR 42.1M
- IPO Year
- KPTI 2013
- IPWR 2013
- Fundamental
- Price
- KPTI $7.36
- IPWR $5.25
- Analyst Decision
- KPTI Strong Buy
- IPWR Hold
- Analyst Count
- KPTI 5
- IPWR 1
- Target Price
- KPTI $61.00
- IPWR N/A
- AVG Volume (30 Days)
- KPTI 101.5K
- IPWR 23.1K
- Earning Date
- KPTI 05-12-2025
- IPWR 05-15-2025
- Dividend Yield
- KPTI N/A
- IPWR N/A
- EPS Growth
- KPTI N/A
- IPWR N/A
- EPS
- KPTI N/A
- IPWR N/A
- Revenue
- KPTI $145,237,000.00
- IPWR $86,032.00
- Revenue This Year
- KPTI $4.87
- IPWR $18.56
- Revenue Next Year
- KPTI $16.29
- IPWR $9,900.00
- P/E Ratio
- KPTI N/A
- IPWR N/A
- Revenue Growth
- KPTI N/A
- IPWR N/A
- 52 Week Low
- KPTI $3.51
- IPWR $3.77
- 52 Week High
- KPTI $18.00
- IPWR $9.69
- Technical
- Relative Strength Index (RSI)
- KPTI 68.69
- IPWR 53.42
- Support Level
- KPTI $5.52
- IPWR $4.80
- Resistance Level
- KPTI $6.56
- IPWR $5.45
- Average True Range (ATR)
- KPTI 0.56
- IPWR 0.48
- MACD
- KPTI 0.34
- IPWR 0.04
- Stochastic Oscillator
- KPTI 86.12
- IPWR 55.92
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About IPWR Ideal Power Inc.
Ideal Power Inc is pioneering the development of its broadly patented bidirectional power switches, creating efficient and ecofriendly energy control solutions for electric vehicles, electric vehicle charging, renewable energy, energy storage, UPS / data center, solid-state circuit breaker and other industrial and military applications. The company is focused on its patented Bidirectional, Bipolar Junction Transistor (B-TRAN) semiconductor technology. B-TRAN is a double-sided bidirectional AC switchable to deliver substantial performance improvements over conventional power semiconductors. The primary raw material used in the fabrication of B-TRAN devices is silicon wafers.